Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma
James R. Berenson(Oncotherapeutics (United States)), Robert Vescio(Royal Adelaide Hospital), Eli Forouzan(Oncotherapeutics (United States)), Regina A. Swift(Institute for Myeloma & Bone Cancer Research), Honghao Yang, Shahrooz Eshaghian(Cedars-Sinai Medical Center), Benjamin Eades(James Madison University), Tanya M. Spektor(Oncotherapeutics (United States)), Tahmineh Safaie(Oncotherapeutics (United States)), Noemi Silagan(Oncotherapeutics (United States)), Mehdi M. Moezi, Stephen Lim(Cedars-Sinai Medical Center), Ralph V. Boccia(Center for Cancer and Blood Disorders), Gary K. Schwartz(Baylor University Medical Center), Jennifer To(Oncotherapeutics (United States)), Daisy Martinez(Oncotherapeutics (United States))
Cited by 1
Related Papers
Tumour exosome integrins determine organotropic metastasis
|Nature|2015|5.2k
Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry
|Journal of Clinical Oncology|2005|1.1k
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
|Nature Genetics|2010|725